NEW YORK — Veranome Biosystems has partnered with Portal Bioscience to develop new spatial transcriptomics products for research in cancer and other complex diseases, the companies said on Thursday.
The new products will use Veranome's high-definition imaging and data analysis technologies with Portal's Proxal probe ligation-based biochemistry to enable the tracking of fragmented RNA, such as that found in formalin-fixed, paraffin-embedded specimens, as well as the detection of mutations, gene fusions, and splice variants.
Specific terms of the deal were not disclosed.
"Understanding complex tissue architectures, such as the tumor-immune microenvironment, requires robust spatial omics technologies that work on routinely fixed and paraffin-embedded clinical specimens," Ben Larman, scientific cofounder of Portal, noted in a statement
Mountain View, California-based Veranome, a spinout of Singapore's A*STAR, offers research services based on its Pisces platform for single-cell data visualization and analysis. Portal, based in Baltimore, is developing RNA analysis products based on technologies exclusively licensed from Johns Hopkins University.